United Therapeutics (UTHR) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $7.27
- EPS estimate
- $6.86
- EPS surprise
- +5.95%
- Revenue surprise
- −2.65%
- Revenue
- $783.3M
- Revenue estimate
- $804.6M
- Reported
- Aug 5, 2026
United Therapeutics reported Q2 2026 results on August 5, 2026. Earnings per share were $7.27, ahead of the $6.86 estimate by 5.95%. Revenue of $783.3 million fell short of the $804.6 million consensus by 2.65%. Compared with Q2 2025, EPS rose about 13% from $6.41, while revenue slipped about 2% from $798.6 million.
Over the longer run, growth has been strong. Annual EPS rose from $15.02 in 2022 to $19.84 in 2023, $24.60 in 2024 and $27.90 in 2025. Revenue grew from $1.94 billion to $3.18 billion over the same years. Recently it has flattened, holding between $781.5 million and $799.5 million in each of the last six quarters. First-half 2026 EPS was $13.09, almost unchanged from $13.04 a year earlier. Results against estimates are uneven: United Therapeutics beat the EPS estimate 9 times in the last 20 quarters, with misses as large as 45.09% in Q2 2022.
United Therapeutics reported Q3 between October 29 and November 3 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue moves out of the narrow band of recent quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $6.86 | $7.27 | +5.95% | $783.3M | SEC |
| Q1 2026 | May 6, 2026 | $7.00 | $5.82 | −16.83% | $781.5M | SEC |
| Q4 2025 | Feb 25, 2026 | $6.87 | $7.70 | +12.06% | $790.2M | SEC |
| Q3 2025 | Oct 29, 2025 | $7.32 | $7.16 | −2.14% | $799.5M | SEC |
| Q2 2025 | Jul 30, 2025 | $7.30 | $6.41 | −12.13% | $798.6M | SEC |
| Q1 2025 | Apr 30, 2025 | $6.70 | $6.63 | −0.99% | $794.4M | SEC |
| Q4 2024 | Feb 26, 2025 | $6.40 | $6.19 | −3.28% | $735.9M | SEC |
| Q3 2024 | Oct 30, 2024 | $6.52 | $6.39 | −2.04% | $748.9M | SEC |
| Q2 2024 | Jul 31, 2024 | $6.51 | $5.85 | −10.07% | $714.9M | SEC |
| Q1 2024 | May 1, 2024 | $5.74 | $6.17 | +7.44% | $677.7M | SEC |
| Q4 2023 | Feb 21, 2024 | $4.19 | $4.36 | +4.13% | $614.7M | SEC |
| Q3 2023 | Nov 1, 2023 | $5.10 | $5.38 | +5.45% | $609.4M | SEC |
| Q2 2023 | Aug 2, 2023 | $4.57 | $5.24 | +14.69% | $596.5M | SEC |
| Q1 2023 | May 3, 2023 | $4.59 | $4.86 | +5.92% | $506.9M | SEC |
| Q4 2022 | Feb 22, 2023 | $4.72 | $2.67 | −43.46% | $491.5M | SEC |
| Q3 2022 | Nov 2, 2022 | $3.91 | $4.91 | +25.59% | $516.0M | SEC |
| Q2 2022 | Aug 3, 2022 | $4.39 | $2.41 | −45.09% | $466.9M | SEC |
| Q1 2022 | May 4, 2022 | $3.65 | $5.03 | +37.94% | $461.9M | SEC |
| Q4 2021 | Feb 24, 2022 | $3.58 | $3.51 | −1.96% | $415.2M | SEC |
| Q3 2021 | Nov 3, 2021 | $3.59 | $3.42 | −4.80% | $444.7M | SEC |
Quarterly revenue
Frequently asked questions
When did United Therapeutics (UTHR) last report earnings?
United Therapeutics last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did UTHR beat earnings estimates?
Yes. United Therapeutics reported EPS of $7.27 for Q2 2026 against a $6.86 estimate — a 5.95% beat.
How much revenue did UTHR report last quarter?
United Therapeutics reported $783.3M in revenue for Q2 2026, against a consensus estimate of $804.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.